Correspondence | Published:

Fabry disease cardiac variant IVS4+919 G>A is associated with multiple cardiac gene variants in patients with severe cardiomyopathy and fatal arrhythmia

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Hsu MJ, Chang FP, Lu YH, et al. Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients. Genet Med. 2018 Jun 6; [Epub ahead of print].

  2. 2.

    Chien YH, Lee NC, Chiang SC, Desnick RJ, Hwu WL. Fabry disease: incidence of the common later-onset alpha-galactosidase A IVS4+919G–>A mutation in Taiwanese newborns—superiority of DNA-based to enzyme-based newborn screening for common mutations. Mol Med. 2012;18:780–784.

  3. 3.

    Chiang HL, Wang NH, Song IW, et al. Genetic epidemiological study doesn’t support GLA IVS4+919G>A variant is a significant mutation in Fabry disease. Mol Genet Metab. 2017;121:22–27.

  4. 4.

    Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am J Hum Genet. 1993;53:1186–1197.

Download references

Author information

Correspondence to Yin-Hsiu Chien MD, PhD.

Ethics declarations


The authors declare no conflicts of interest. This study was approved by the National Taiwan University Hospital Institutional Review Board (No. 201505135RINA).

Additional information

Ethics approval and consent to participate: This study was approved by the institutional review board.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading